guest ::
| Home > Publications database > Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. > print |
| Home > Publications database > Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. > print |
| 001 | 181300 | ||
| 005 | 20240229145644.0 | ||
| 024 | 7 | _ | |a 10.1038/s41416-022-01932-1 |2 doi |
| 024 | 7 | _ | |a pmid:35986087 |2 pmid |
| 024 | 7 | _ | |a 0007-0920 |2 ISSN |
| 024 | 7 | _ | |a 1532-1827 |2 ISSN |
| 024 | 7 | _ | |a altmetric:134775838 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01927 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Tomczak, Aurelie |b 0 |
| 245 | _ | _ | |a Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. |
| 260 | _ | _ | |a Edinburgh |c 2022 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1666967173_11984 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2022 Nov;127(9):1701-1708 |
| 520 | _ | _ | |a Advanced cholangiocarcinoma has a poor prognosis. Molecular targeted approaches have been proposed for patients after progression under first-line chemotherapy treatment. Here, molecular profiling of intrahepatic cholangiocarcinoma in combination with a comprehensive umbrella concept was applied in a real-world setting.In total, 101 patients received molecular profiling and matched treatment based on interdisciplinary tumour board decisions in a tertiary care setting. Parallel DNA and RNA sequencing of formalin-fixed paraffin-embedded tumour tissue was performed using large panels.Genetic alterations were detected in 77% of patients and included gene fusions in 21 patients. The latter recurrently involved the FGFR2 and the NRG1 gene loci. The most commonly altered genes were BAP1, ARID1A, FGFR2, IDH1, CDKN2A, CDKN2B, PIK3CA, TP53, ATM, IDH2, BRAF, SMARCA4 and FGFR3. Molecular targets were detected in 59% of patients. Of these, 32% received targeted therapy. The most relevant reason for not initiating therapy was the deterioration of performance status. Patients receiving a molecular-matched therapy showed a significantly higher survival probability compared to patients receiving conventional chemotherapy only (HR: 2.059, 95% CI: 0.9817-4.320, P < 0.01).Molecular profiling can be successfully translated into clinical treatment of intrahepatic cholangiocarcinoma patients and is associated with prolonged survival of patients receiving a molecular-matched treatment. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Springfeld, Christoph |b 1 |
| 700 | 1 | _ | |a Dill, Michael T |0 P:(DE-He78)54a6641a6c26ddc49cc754740e90b438 |b 2 |u dkfz |
| 700 | 1 | _ | |a Chang, De-Hua |b 3 |
| 700 | 1 | _ | |a Kazdal, Daniel |0 0000-0001-8187-3281 |b 4 |
| 700 | 1 | _ | |a Wagner, Ursula |b 5 |
| 700 | 1 | _ | |a Mehrabi, Arianeb |b 6 |
| 700 | 1 | _ | |a Brockschmidt, Antje |b 7 |
| 700 | 1 | _ | |a Luedde, Tom |0 0000-0002-6288-8821 |b 8 |
| 700 | 1 | _ | |a Naumann, Patrick |b 9 |
| 700 | 1 | _ | |a Stenzinger, Albrecht |b 10 |
| 700 | 1 | _ | |a Schirmacher, Peter |b 11 |
| 700 | 1 | _ | |a Longerich, Thomas |0 0000-0001-8888-1030 |b 12 |
| 773 | _ | _ | |a 10.1038/s41416-022-01932-1 |0 PERI:(DE-600)2002452-6 |n 9 |p 1701-1708 |t British journal of cancer |v 127 |y 2022 |x 0007-0920 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:181300 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)54a6641a6c26ddc49cc754740e90b438 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRIT J CANCER : 2021 |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-15 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-15 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BRIT J CANCER : 2021 |d 2022-11-15 |
| 920 | 1 | _ | |0 I:(DE-He78)F240-20160331 |k F240 |l NWG Experimentelle Hepatologie, Entzündung und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F240-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|